The drug will be provided to the NHS free of charge by Gilead via the UK’s early access to medicines scheme
News
Novavax launches trial of coronavirus vaccine candidate
The firm has begun enrolling patients in the Phase I portion of the trial
New US approval for Takeda’s Alunbrig
The move is based on data showing Alunbrig’s superiority over crizotinib as first-line treatment of metastatic ALK+ NSCLC
Sanofi to sell stake in Regeneron
The move does not affect the firms’ ongoing collaboration
AZ links with ArcherDX to detect minimal residual disease in lung cancer patients
ArcherDX will perform whole exome sequencing of NSCLC patient samples to generate personalised ctDNA assays to test for MRD
WHO pauses hydroxycholoroquine arm in COVID-19 trial
The Solidarity trial’s expert group will review all evidence available on the drug
Gov’t unveils coronavirus antibody testing scheme
10 million tests have so far have been secured in a ‘landmark deal’ with industry, including Roche Diagnostics and Abbott Labs
Gov’t invests £7m in patient recruitment centres for clinical research
The sites will be managed by the National Institute for Health Research (NIHR) and run by NHS trusts
GSK partners with Samsung to expand biopharma manufacturing
Samsung will provide GSK with additional flexible capacity for large-scale biopharmaceutical product manufacturing
NICE u-turn backs Roche’s Tecentriq for triple negative breast cancer
Tecentriq is the first and only immune checkpoint inhibitor which has been deemed a cost effective use of NHS resources for this patient group
Researchers investigate impact of lockdown on musculoskeletal conditions
The research will focus on people with psoriatic arthritis, axial spondyloarthritis and chronic pain conditions such as fibromyalgia
First UK healthcare worker to enrol in COVID-19 prevention trial
Over 130 UK frontline healthcare workers have lost their lives during the pandemic
UK risks second surge of coronavirus without clarity on test, track and trace
The NHS Confederation is calling on the government for a clear strategy before lockdown measures are further lifted
AZ/MSD’s Lynparza wins prostate cancer approval
Lynparza is the only PARP inhibitor to improve overall survival versus enzalutamide or abiraterone in prostate cancer patients with BRCA1/2 or ATM mutations
People with diabetes at higher risk of amid pandemic
The overall death rate for people with diabetes doubled during the early stage of the pandemic
